FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical Trials of Company’s Parkinson’s Disease Treatment with Approval from U.S. Food and Drug AdministrationRead Now >
Wednesday, November 17, 2021 / PRWeb
The latest updates on drug candidate KM-819.
FDA Approval Sought to Begin Phase 2 Trial of KM-819Read Now >
Wednesday, November 17, 2021 / Parkinson's News Today
FAScinate Therapeutics Inc. Submits Investigational New Drug (IND) Application for Phase 2 Clinical Studies of Company's New Parkinson's Disease TreatmentRead Now >
Friday, November 5, 2021 / FAScinate Therapeutics